{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:52:01Z","timestamp":1790970721531,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T00:00:00Z","timestamp":1138147200000},"content-version":"vor","delay-in-days":1881,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2000,12]]},"abstract":"<jats:p><jats:bold>A<jats:sc>bstract<\/jats:sc>: <\/jats:bold> It has been shown over the past few years that apolipoprotein E (apoE) plays a central role in the brain response to injury and neurodegeneration in mammalian species. The coordinated expression of apoE and its different receptors, the so\u2010called LDL receptor family, appears to regulate the transport of cholesterol and phospholipids during the early and middle phases of the reinnervation in the adult mammalian brain. As neurons undergo dendritic remodelling and synaptogenesis using cholesterol internalization through the apoE\/LDL receptor pathway, they progressively shut down 3,3\u2010hydroxymethylglutaryl\u2010Coenzyme A (HMG CoA) reductase activity, the rate\u2010limiting enzyme in the synthesis of cholesterol. These results suggest that cholesterol delivery and synthesis in the brain are tightly regulated through an apoE\u2010dependent mechanism. The discovery that the apolipoprotein e4 allele is strongly linked to both sporadic and familial late\u2010 onset Alzheimer's disease (AD) has raised the possibility that a dysfunction of lipid transport could explain the poor compensatory synaptogenesis reported by several independent research groups in the brain of AD subjects. Recently, it has been shown that alterations of cholesterol homeostasis in the brain by exogenous administration of dietary cholesterol, or through inhibition of cholesterol synthesis, markedly affect beta amyloid production (1\u201340 and 1\u201342) and deposition and significantly impair amyloid precursor protein (APP) metabolism. <jats:italic>In vivo<\/jats:italic>, it has been shown that breeding of APP\u2010overexpressing mice with apoE knockout mice completely abolishes amyloid plaque deposition in the brain of hybrid animals, without affecting beta amyloid steady state levels. Conversely, introduction of the human apoE3 and apoE4 genes in APP\u2010 overexpressing mice drastically reduced beta amyloid deposition in the brain of hybrid mice, confirming the proposed biological role of apoE in the clearance of extracellular beta amyloid. These results indicate that lipid homeostasis is controlled in large part by the apoE lipoprotein transport system in the extracellular space, whereas alterations in intracellular lipid homeostasis markedly affect APP processing, beta amyloid production and plaque formation <jats:italic>in vivo<\/jats:italic>. The convergence of the so\u2010 called amyloid cascade hypothesis (Hardy <jats:italic>et al.<\/jats:italic>, 1992) and of the apoE\/lipid recycling cascade model (Poirier, 1994) is consistent with the notion that alterations in lipid homeostasis could serve as the common denominator for apoE and beta amyloid dysfunctions in Alzheimer's disease. It is also interesting to note that lipid homeostasis is also a central feature of one of the most important neurotransmitter systems in the brain: the cholinergic system. This system is unique in the CNS since it relies heavily on lipid bioavailability to locally synthesize acetylcholine. It is thus quite tempting to propose that two of the most common neuropathologic landmarks of AD \u2010 namely, cholinergic dysfunction and amyloid deposition \u2010 may in fact depend on the integrity of local lipid homeostatic processes, which in turn are strongly dependent upon proper lipid delivery by the apoE transport system.<\/jats:p>","DOI":"10.1111\/j.1749-6632.2000.tb05564.x","type":"journal-article","created":{"date-parts":[[2010,7,20]],"date-time":"2010-07-20T20:58:16Z","timestamp":1279659496000},"page":"81-90","source":"Crossref","is-referenced-by-count":115,"title":["Apolipoprotein E and Alzheimer's Disease A Role in Amyloid Catabolism"],"prefix":"10.1111","volume":"924","author":[{"given":"JUDES","family":"POIRIER","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,1,25]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.4.1125"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI113943"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0169-328X(91)90002-F"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0169-328X(91)90111-A"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(93)90456-P"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.102.2.393"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3283935"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.76.9.4646"},{"key":"e_1_2_6_10_2","unstructured":"Masliah E. & M. Mallory. 1995. Abnormal synaptic regeneration in apoE\u2010 knockout.InResearch Advances in Alzheimer's and Related Disorders. K. Iqbal J.A. Mortimer B Winblad and H.M. Wishniewski Eds.: 405\u2013414. John Wiley. New York."},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1998.6818"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.6474172"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.4071042"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410210307"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.17-02-00516.1997"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8171342"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.19-12-04867.1999"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1996.tb34415.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91728-5"},{"key":"e_1_2_6_20_2","doi-asserted-by":"crossref","first-page":"8098","DOI":"10.1073\/pnas.90.17.8098","article-title":"Binding of human apolipoprotein E to synthetic amyloid \u03b2\u2010peptide: isoform\u2010specific effect and implication for late onset Alzheimer's disease","volume":"90","author":"Strittmatter W.J.","year":"1993","journal-title":"Proc. Natl. Acad. Sci."},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1993.1423"},{"key":"e_1_2_6_22_2","doi-asserted-by":"crossref","first-page":"23403","DOI":"10.1016\/S0021-9258(17)31529-6","article-title":"Isoform\u2010specific binding of apolipoprotein E to beta amyloid J","volume":"269","author":"Ladu M.J.","year":"1994","journal-title":"Biol. Chem."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6273(93)90070-8"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.20.9649"},{"key":"e_1_2_6_25_2","unstructured":"Emmerling M.R. S. Gracon & A.E. Roher. 1999. Toward a unifying hypothesis of Alzheimer's disease pathogenesis and pathophysiology.InClinical Diagnosis and Management of Alzheimer's Disease 2nd edit. S. Gauthier Ed.: 33\u201353. Martin Dunitz. London."},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(99)01894-6"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1197-263"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.26.16576"},{"key":"e_1_2_6_29_2","doi-asserted-by":"crossref","unstructured":"Holtzman D.M. K.R. Bales S. Wu et al. 1999. Expression of human apolipoprotein E reduces amyloid deposition in a mouse model of Alzheimer's disease. J. Clin. Invest. 103: 1521.","DOI":"10.1172\/JCI6179"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.11.6460"},{"key":"e_1_2_6_31_2","unstructured":"Wolosin B. W. Kellman G. Celesia & G. Siegel. 1999. Decreased prevalence of Alzheimer's disease associated with the use of HMG COA reductase inhibitors. Soc. Neurosci. Abstr. 25: 16."},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1998.70041458.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-328X(99)00073-X"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-6632.2000.tb05564.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-6632.2000.tb05564.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T08:01:18Z","timestamp":1695628878000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.2000.tb05564.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,12]]}},"alternative-id":["10.1111\/j.1749-6632.2000.tb05564.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1749-6632.2000.tb05564.x","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,12]]}}}